BioStock: Positive subgroup data in SynAct Pharmas’s EXPAND study

Biotech SynAct Pharma has unveiled additional data from its EXPAND phase II clinical trial with resomelagon for rheumatoid arthritis. The new findings indicate consistent responsiveness to the drug candidate in a sub-population of patients with c-reactive protein level exceeding 3 mg/L, which is an indicative for active systemic inflammation. These encouraging findings are important for further development of resomelagon, according to the company’s CSO Thomas Jonassen in an interview. 

Read the full article at biostock.se:

https://www.biostock.se/en/2023/09/positive-subgroup-data-in-synact-pharmass-expand-study/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se